covaxin
Bharat Biotech has approached apex body Drug Controller General India’s (DCGI) to give nod for nasal Covid-19 vaccine trials in India.
After giving approval to two indigenous corona vaccines for emergency use in India, developed by pharma major Bharat Biotech and Serum Institutes, Bharat Biotech has come up with new form of vaccines and has sought approval from DGCI. Bharat Biotech has approached apex body Drug Controller General India’s (DCGI) to give nod for nasal Covid-19 vaccine trials in India.
Bharat Biotech has already got approval for Covaxin for emergency use against COVID19. Important is that it is still conducting phase-3 trials in India.
Krishna Ella, Chairman and Managing Director of Bharat Biotech, says that this nasal vaccine has potential to revolutionise Indian vaccine making capabilities and help the country leapfrog along with Europe, the US and China.
A study published in scientific journal Cell points out that animal studies on nasal vaccine – single dose intra-nasal ChAd vaccine – protects upper and lower respiratory tracts against SARS-CoV-2. Along with, this vaccine has shown 100 per cent sterilising ability in monkeys.
Under the Yellow Ribbon Campaign conceptualized in 1998 by Dr S K Sarin with the…
In a written reply to a question in the Rajya Sabha, Union Health Minister J…
India achieved 48.7 per cent decline in annual new HIV infections and 81.4 per cent reduction in AIDS-related…
In a significant medical achievement, doctors at HCMCT Manipal Hospital Dwarka, New Delhi, successfully performed…
Preventive health checks play a crucial role in identifying pollution-related risks early, especially for smokers,…
The Winter Session of Parliament has begun from Monday with a packed legislative agenda, including…